Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. (Q53921000)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. |
scientific article |
Statements
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer (English)
Bernard A Zonnenberg
Gerard Groenewegen
Todd J Janus
Terri W Leahy
Rod A Humerickhouse
Jeffrey D Isaacson
Robert A Carr
1 August 2003